News

Sigyn Therapeutics Announces Live Presentation at Investor Forum

Sigyn Therapeutics Announces Live Presentation at Investor Forum

Sigyn Therapeutics' Upcoming Presentation

Excitement is building as Sigyn Therapeutics, Inc. (OTCQB: SIGY), a pioneer in creating innovative therapies for cardiovascular disease and cancer, prepares for a live presentation at the Life Sciences Virtual Investor Forum. This event will take place soon and is expected to draw considerable interest from investors eager to learn more about the Company's groundbreaking advancements.

Details of the Event

The presentation is scheduled for September 18 at 3:00 PM ET. Jim Joyce, the Chairman and CEO of Sigyn Therapeutics, will deliver the opening remarks, sharing vital insights and developments directly with potential investors. This interactive online event not only allows for real-time engagement but also ensures that those unable to attend can access an archived version later.

Why Attendance Matters

This event represents a significant opportunity for investors to engage with the latest advancements at Sigyn Therapeutics. By pre-registering, potential attendees can expedite their participation and ensure they receive updates related to the event, enhancing their experience.

Recent Company Highlights

Recently, Sigyn Therapeutics introduced Sigyn Therapy™, revolutionizing the approach to treating cardiovascular disease. As the leading cause of death globally, this innovative device aims to reduce inflammatory molecules and cholesterol-carrying lipoproteins associated with major cardiovascular events. This first-in-class technology paves the way for more effective treatment pathways, potentially decreasing adverse event rates significantly.

Innovative Approach to Cancer Therapies

In addition to its cardiovascular innovations, Sigyn Therapeutics is also navigating the complex landscape of cancer treatments. Their suite of therapies includes ImmunePrep™, ChemoPrep™, and ChemoPure™, specifically designed to enhance immunotherapy delivery, optimize chemotherapy administration, and mitigate toxic side effects. The Company's commitment to advancing these therapies through strategic partnerships exemplifies their proactive approach in a competitive market.

Exploring the Technology

The uniqueness of Sigyn Therapy™ lies in its design that not only targets inflammatory dangers but also specifically focuses on eliminating low-density lipoprotein cholesterol from the bloodstream. Through this external device, patients may experience a notable reduction in the risks associated with heart attacks, strokes, and other cardiovascular complications.

About Sigyn Therapeutics

Sigyn Therapeutics is pivotal in developing dialysis-like treatments for some of today's most challenging health issues, such as cardiovascular disease and cancer. By utilizing a whole blood adsorption technology, Sigyn aims to significantly impact the therapeutic landscape, making their offerings crucial for patients at risk of far-reaching health consequences.

About Virtual Investor Conferences

The Virtual Investor Conference series is known for bridging the gap between publicly traded companies and investors. Offering seamless presentations and real-time interaction, this platform stands out in today’s fast-evolving financial ecosystem.

Contact Information

Sigyn Therapeutics, Inc.
Jim Joyce
CEO, Inventor
Email: jj@SigynTherapeutics.com

Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

Frequently Asked Questions

What is Sigyn Therapeutics focused on?

Sigyn Therapeutics develops therapies to address cardiovascular issues and cancer, particularly through innovative dialysis-like technologies.

When will the virtual presentation take place?

The virtual presentation by Sigyn Therapeutics is on September 18, at 3:00 PM ET.

How can investors participate in the event?

Investors can pre-register for the event to receive updates and expedited access to the presentation.

What is the significance of Sigyn Therapy™?

Sigyn Therapy™ represents a breakthrough in targeting inflammatory molecules and lipoproteins related to cardiovascular disease.

Who can I contact for more information?

For inquiries, you can reach out to Jim Joyce directly via email at jj@SigynTherapeutics.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gemmy's Holiday Lights: Bright Ideas for 2026

Updated Category News Views 149

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...

Continue Reading
IM Cannabis's Third Quarter Financial Jolt

Updated Category News Views 143

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 132

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 177

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Chime Joins S&P MidCap 400 Amid Merger Jostle

Updated Category News Views 194

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Continue Reading
Perpetua Reports Q3 2026 Results, Progress on Project

Updated Category News Views 81

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 150

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 53

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
55 Broad Street's New Face: A $500M Revamp with RXR

Updated Category News Views 189

Recapitalization: Changing the Game for 55 Broad Street Here we are again, watching yet another iconic Manhattan building redefine itself. This time, it's 55 Broad Street's turn, as Silverstein, MetroLoft, and RXR shake things up. Newmark Group, Inc. (NASDAQ: NMRK), the fiery real estate power player, orchestrated a dynamic transaction involving a $305 million financing...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 107

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

Laurie Jennings to be Honored with Trish Bell Award in 2025

Updated Category News Views 600

Laurie Jennings to be Honored During Fashion Luncheon Chapman Partnership is thrilled to announce that six-time Emmy Award-winning journalist, Laurie Jennings, will receive the Trish Bell Lifetime Achievement Award at the esteemed Take a Walk in Her Shoes Luncheon. This remarkable event is set to take place at Jungle Island in 2025. It will bring together a large number...

Continue Reading
LEIFRAS Co., Ltd. Sets Price for Initial Public Offering

Updated Category News Views 329

LEIFRAS Co., Ltd. Sets Price for Initial Public Offering LEIFRAS Co., Ltd. (the "Company" or "Leifras"), a prominent player in the sports sector, dedicated to promoting youth sports and community initiatives, has unveiled the pricing details for its Initial Public Offering (IPO). IPO Pricing and Details The Company plans to offer 1,250,000 American Depositary Shares...

Continue Reading
Insight into NCC Group plc's Recent Trading Activities

Updated Category News Views 206

Key Insights on NCC Group plc's Trading Activities In the bustling financial markets, transparency is paramount, particularly when it comes to the dealings of exempt principal traders. Today, we delve into the recent activities surrounding NCC Group plc, guided by Rule 8.5 of the Takeover Code. This code ensures that all parties involved maintain clarity in their trading...

Continue Reading
Equifax Unveils AI Advisory Service for Lenders' Success

Updated Category News Views 229

Empowering Lenders with Equifax Ignite AI Advisor Equifax has recently launched a transformative tool known as the Equifax Ignite AI Advisor, which is set to revolutionize how lenders operate. This innovative product aims to provide lenders with precise, actionable insights that can significantly improve decision-making processes and account growth. By leveraging advanced...

Continue Reading
Aligned Partners with AMD and USC ISI for AI Innovation

Updated Category News Views 196

Aligned Teams Up with AMD and USC ISI for AI Advancements Aligned, an innovator in AI infrastructure and scalable machine learning, has announced an exciting collaboration with AMD and USC ISI. This partnership aims to propel the development of MEGALODON, a groundbreaking large language model (LLM). By leveraging AMD's powerful Instinct™ MI300 GPUs and Aligned's...

Continue Reading